| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the acceptance for publication of the manuscript, "Clinical Validation of a Genetic Model to Estimate the Risk of Developing Choroidal Neovascular Age-related Macular Degeneration." The article will appear in the June issue of Human Genomics. The study, conducted by the company's wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), was modeled using approximately 2000 case and control samples obtained from the University of Iowa, the University of Utah, Harvard University, Columbia University and the University of Melbourne.
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)
The successful completion and peer reviewed acceptance of this study for publication coincides with the introduction of RetnaGene™ AMD, a laboratory developed test (LDT) to assess the risk of developing Choroidal Neovascularization (CNV), the wet form of age-related macular degeneration (AMD), a common eye disorder of the elderly that can lead to blindness. The comprehensive set of genetic markers genotyped at the study centers were tested in a model to demonstrate the clinical validation of RetnaGene AMD LDT, providing the first commercial validation performed on a large collection of patients specifically targeting CNV.
"The LDT was designed to provide the most accurate assessment of risk based solely on genetic markers that are static through life and avoided inclusion of self-reported variables (e.g. smoking history) or non-static factors (BMI, education status) that might otherwise introduce inaccuracies in calculating a patient's risk of disease," said the lead author of the study, Dr. Gr
'/>"/>
| SOURCE Sequenom, Inc. Copyright©2010 PR Newswire. All rights reserved |